Androbloc® contains the active substance bicalutamide.
Bicalutamide belongs to a group of medicines called antiandrogens. It works by blocking the effects of male hormones, such as testosterone.
Androbloc® 50 mg is used to treat patients with advanced prostate cancer in combination with LHRH analogue therapy or surgical castration.
Androbloc®150 mg is indicated either as sole therapy or adjuvant to radical prostatectomy or radiotherapy in patients with locally advanced prostate cancer at high risk of progression.
Androbloc® 150 mg is also indicated for the treatment of patients with locally advanced, non-metastatic prostate cancer in whom surgical castration or other medical intervention is not considered appropriate or acceptable.